About
About Shanghai Hile Bio-Technology Co., Ltd
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent assay reagents, and related diagnostic kits, including immunoglobulin G subtype 4, helicobacter pylori, adiponectin, creatine kinase isoenzyme, hepatobiliary acid, cardiac troponin I, heparin binding protein, N-acetyl-O-D-glucosidase, muscle soda, salivary glycan antigen KL-6 kits. It also provides oral bone repair materials, implants, natural bone repair materials, dental restorative materials, collagen-based bone repair matrix, and soft tissue repair matrix. The company was founded in 1981 and is based in Shanghai, China.
Visit company website
5 years, 5 months ago
Shanghai Hile Bio-Technology Co., Ltd is currently in a long term downtrend where the price is trading 5.4% below its 200 day moving average.
From a valuation standpoint, the stock is 328.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 41.3.
Shanghai Hile Bio-Technology Co., Ltd's total revenue sank by 1.2% to $77M since the same quarter in the previous year.
Its net income has dropped by 35.0% to $5M since the same quarter in the previous year.
Finally, its free cash flow fell by 105.8% to $-6M since the same quarter in the previous year.
Based on the above factors, Shanghai Hile Bio-Technology Co., Ltd gets an overall score of 0/5.